NASDAQ:CELG
Delisted
Celgene Corporation Stock News
$108.24
+0 (+0%)
At Close: Jan 16, 2020
Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)
01:07pm, Wednesday, 13'th Mar 2024
Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)
Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript)
06:48pm, Thursday, 04'th Jan 2024
Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript)
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Bristol-Myers Squibb Company
06:44pm, Wednesday, 06'th Oct 2021
NEW YORK--(BUSINESS WIRE)--ENTWISTLE & CAPPUCCI LLP FILES A SECURITIES CLASS ACTION COMPLAINT AGAINST BRISTOL-MYERS SQUIBB COMPANY
Why the Growth Isn't Over for This Best-in-Breed Biotech Stock
08:32am, Saturday, 13'th Mar 2021
It's not getting much attention lately, but the future for Amgen looks strong.
Bristol Myers posts $10 billion loss as it books charges relating to MyoKardia and Celgene
07:21am, Thursday, 04'th Feb 2021
Bristol Myers Squibb Co. said Thursday it had a net loss of $10.027 billion, or $4.45 a share, in the fourth quarter, wider than the loss of $1.056 billion, or 55 cents a share, posted in the year-ear
Celgene-Backed Antengene Climbs On Hong Kong Debut
10:02pm, Saturday, 21'st Nov 2020
China's influence in the global pharmaceutical industry is on the rise
